Skip to main content
    S

    Skye Bioscience, Inc. Common Stock (SKYE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.06
    -0.03 (-2.29%)

    Market Cap: $4.83M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Skye Bioscience, Inc. Common Stock (SKYE) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Skye Bioscience, Inc. Common Stock are PharmaCyte Biotech (PMCB), CNS Pharmaceuticals (CNSP) and Ensysce Biosciences (ENSC). By market cap, Skye Bioscience, Inc. Common Stock ranks 5th of the 13 companies on this page; Ensysce Biosciences (ENSC) is the largest at $8.14M.

    Peer Comparison

    SKYE's ROIC of -3685.3% is below the peer median of -247.2%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Skye Bioscience, Inc. Common Stock (SKYE)$4.83MN/AN/A0.0%-3685.3%0.0%0.00%
    PharmaCyte Biotech Inc (PMCB)$3.77MN/AN/A0.0%N/A0.0%0.00%
    CNS Pharmaceuticals Inc (CNSP)$4.22MN/AN/A0.0%N/A0.0%0.00%
    Ensysce Biosciences Inc (ENSC)$8.14MN/A1.2x-280.5%-260.6%-15.1%0.00%
    Processa Pharmaceuticals Inc (PCSA)$5.20MN/AN/A0.0%N/A0.0%0.00%
    Kiora Pharmaceuticals Inc (KPRX)$5.44MN/A6.2x0.0%N/A0.0%0.00%
    Exicure Inc (XCUR)$7.07MN/AN/A0.0%N/A928.0%0.00%
    Azitra Inc (AZTR)$3.69MN/AN/A0.0%N/A-100.0%0.00%
    Calidi Biotherapeutics Inc. (CLDI)$2.29MN/AN/A0.0%N/A0.0%0.00%
    Liminatus Pharma, Inc. Class A Common Stock (LIMN)$4.02MN/AN/A0.0%-247.2%0.0%0.00%
    GRI Bio Inc. (GRI)$3.72MN/AN/A0.0%N/A0.0%0.00%
    Traws Pharma Inc (TRAW)$3.86MN/AN/A0.0%N/A-100.0%0.00%
    Purple Biotech (PPBT)$2.65MN/AN/A0.0%-156.2%0.0%0.00%
    Peer median$3.94MN/A3.7x0.0%-247.2%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Skye Bioscience, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    PharmaCyte Biotech Inc (PMCB)
    PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United...
    PMCB competitors
    CNS Pharmaceuticals Inc (CNSP)
    CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, is dedicated to the development of cancer drug candidates for the treatment of brain and central...
    CNSP competitors
    Ensysce Biosciences Inc (ENSC)
    Ensysce Biosciences, Inc., a clinical-stage biotechnology company, is dedicated to the development of various prescription drugs.
    ENSC competitors
    Processa Pharmaceuticals Inc (PCSA)
    Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients...
    PCSA competitors
    Kiora Pharmaceuticals Inc (KPRX)
    Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology firm focused on developing innovative therapies for ocular diseases and neurodegenerative...
    KPRX competitors
    Exicure Inc (XCUR)
    Exicure, Inc., a clinical-stage biotechnology company, develops therapies for neurology, immuno-oncology, inflammatory diseases...
    XCUR competitors
    Azitra Inc (AZTR)
    Azitra Inc, a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live...
    AZTR competitors
    Calidi Biotherapeutics Inc. (CLDI)
    Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer.
    CLDI competitors
    Liminatus Pharma, Inc. Class A Common Stock (LIMN)
    Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is headquartered in LA Palma, California.
    LIMN competitors
    GRI Bio Inc. (GRI)
    GRI Bio Inc. is an innovative biotechnology company focused on leveraging microbiome technology to develop cutting-edge therapeutics in immunology and oncology.
    GRI competitors
    Traws Pharma Inc (TRAW)
    Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States.
    TRAW competitors
    Purple Biotech (PPBT)
    Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United...
    PPBT competitors

    Frequently Asked Questions About SKYE

    Who are Skye Bioscience, Inc. Common Stock's main competitors?

    The companies most similar to Skye Bioscience, Inc. Common Stock include PharmaCyte Biotech (PMCB), CNS Pharmaceuticals (CNSP), Ensysce Biosciences (ENSC), Processa Pharmaceuticals (PCSA) and Kiora Pharmaceuticals (KPRX), listed from the closest match.

    Who is Skye Bioscience, Inc. Common Stock's biggest competitor?

    Ensysce Biosciences (ENSC) is the largest of the similar companies at $8.14M; PharmaCyte Biotech (PMCB) is the closest match by business profile, size, sector and industry.

    How does SKYE stock compare with its competitors?

    SKYE's net margin is 0.0% against a peer median of 0.0%.

    Which of Skye Bioscience, Inc. Common Stock's competitors pays a higher dividend?

    Skye Bioscience, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Skye Bioscience, Inc. Common Stock bigger than its competitors?

    No. Skye Bioscience, Inc. Common Stock is 5th by market cap among the 13 companies on this page; the largest is Ensysce Biosciences (ENSC) at $8.14M.